Formulary e-News:
Having trouble viewing this email? View in a browser.
|
You are subscribed to %%list.name%% as %%emailaddr%%. Unsubscribe.
|
to Formulary e-News
|
|
 |
|
 |
Survey
This month we would like to know...
With the recent announcement of Medco's acquisition by Express Scripts, potentially bringing 2 of the nation's largest PBMs together, what do you see as the most significant implications of such consolidation for the industry?
a) Enhanced competition within the industry, inevitably translating to even lower drug costs for PBM payer clients.
b) Unfair advantages for Express Scripts based upon its size, thus reducing competition and potentially increasing long-term costs for payers.
c) Increased pressures on retail pharmacies forcing more pharmacies out of business.
d) Increased quality of PBM clinical, analytic and administrative services across the industry, as other PBMs strive to stay competitive.
e) Minimal, if any, impact.
|
|
|
Patients discharged from the hospital are at an elevated risk of not continuing their long-term medications for chronic diseases, and ICU admission appears to further increase this risk, according a recent study published August 24 in the Journal of the American Medical Association. Read full article. |
 |
The first step toward a national electronic system that will transform FDA's ability to track the safety of drugs, biologics, and medical devices is up and running, according to a recent press release announcing the Mini-Sentinel pilot project. Read full article. |
|
|
FDA has issued a Safety Announcement warning that serious allergic reactions have been reported with the use of the antipsychotic medication asenapine maleate (Saphris). Read full article.
|
|
Drugs such as Taxol, Cytarabine, Daunorubicin, Doxil, and Leucovorin are in short supply, delaying patients with various forms of cancer from getting the treatments they need or forcing them to seek alternative, possibly less-effective treatments, FDA announced recently. Read full article.
|
|
FDA has approved orphenadrine citrate injection, USP (Sagent Pharmaceuticals), a skeletal muscle relaxant as an adjunct to rest, physical therapy, and other measures to support relief from acute, painful musculoskeletal conditions. Read full article.
|
|
FDA is alerting healthcare professionals that repackaged intravitreal injections of Roche Holdings' Avastin (bevacizumab) have caused a cluster of serious eye infections in the Miami, Fla., area. Read full article.
 |
|
|
|
|
|
Contact Us |
Contact a Formulary editor Click Here
Contact a Formulary sales representative Click Here
Learn about direct mail, reprints and classifieds in Formulary Click Here |
You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.
 Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or
fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
|
|
